Perspective Therapeutics, Inc. (NYSE:CATX) CEO Purchases $49,338.24 in Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor bought 22,026 shares of the company’s stock in a transaction on Friday, March 28th. The shares were bought at an average price of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the acquisition, the chief executive officer now directly owns 59,383 shares in the company, valued at approximately $133,017.92. This trade represents a 58.96 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Perspective Therapeutics Price Performance

Shares of NYSE:CATX traded down $0.17 during midday trading on Tuesday, hitting $1.96. The stock had a trading volume of 891,750 shares, compared to its average volume of 999,366. The business’s 50-day simple moving average is $2.91 and its 200-day simple moving average is $6.19. Perspective Therapeutics, Inc. has a 12 month low of $1.91 and a 12 month high of $19.05.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Y Intercept Hong Kong Ltd acquired a new stake in Perspective Therapeutics in the 4th quarter valued at about $33,000. Intech Investment Management LLC bought a new stake in Perspective Therapeutics in the third quarter valued at approximately $137,000. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics in the fourth quarter valued at approximately $34,000. National Bank of Canada FI boosted its stake in shares of Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after acquiring an additional 10,998 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Perspective Therapeutics during the 3rd quarter worth approximately $152,000. Institutional investors own 54.66% of the company’s stock.

Wall Street Analysts Forecast Growth

CATX has been the topic of a number of research analyst reports. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Wednesday, March 26th. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Scotiabank initiated coverage on Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 target price on the stock. Finally, Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $14.44.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.